Published in Journal of Industrial Engineering and Robotics, Volume 5, Number 4
Written by GHINOIU Cristina-Sorela
Scientific coordinators: Cristian DOICIN

In the response to the COVID-19 pandemic, BioNTech launched the COVID-19 vaccine development program BNT162, based on mRNA technology, in the late January 2020 , to develop COVID-19 vaccine candidates and support the global suply of a post approval vaccine. That said, COVID-19 vaccine and a dynamically growing structure may shift the expectations of BioNTehc’s stakeholders: the expectation of many non-governmental organizations campaining for fair and equitable global access to COVID-19 vaccines for an effective containment of the global pandemic. In the financial year 2020, BioNTech entered into two strategic collaborations with major pharmaceutical companies, Pfizer Inc. of New York, USA, and Fosun Pharmaceutical Industrial Development Co. Ltd. of Shanghai, China, in connection with the BNT162 vaccine program ‚Lightspeed’. [1]

[Read full article] [Citation]